Comparative Pharmacology
Head-to-head clinical analysis: ESTARYLLA versus NORINYL 1 35 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTARYLLA versus NORINYL 1 35 28 DAY.
ESTARYLLA vs NORINYL 1+35 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Norethindrone is a progestogen that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary-ovarian axis, further suppressing ovulation and altering cervical mucus and endometrial thickness.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
One tablet orally once daily for 28 consecutive days (21 active tablets followed by 7 inert tablets).
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Norethindrone: 7-8 hours (terminal half-life); steady state achieved after 5 days. Ethinyl estradiol: biphasic with terminal half-life of 13-27 hours (mean ~17 hours). Clinical context: dosing interval of 24 hours allows stable hormone levels after first cycle.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Renal: 50-60% (conjugates and metabolites), Fecal: 30-40% (biliary elimination of norethindrone and ethinyl estradiol conjugates); total clearance ~4-6 mL/min/kg.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive